Shots:

• Herzuma wins <51% of the market share in Japan in Jun’21 & secured the top position with the reliability proved by the expanding prescriptions globally. Celltrion is co-promoting Herzuma along with Nippon Kayaku
• Celltrion also mentioned the Japanese government's policy change as another factor to affect Herzuma prescription positively. Tokyo has added a policy to promote biosimilar drugs in Prime Minister Yoshihide Suga's Honbebuto Paper in Jun’21
• Celltrion has declared the bids for Herzuma & Truxima in Brazil and Japan. The company plans to launch Remsima (infliximab) & Yuflyma (adalimumab)

| Ref: Businesswire | Image: Celltrion